

PRODUCT INFORMATION



MBX-8025 (sodium salt)

Item No. 28761

Formal Name: (R)-2-(4-((2-ethoxy-3-(4-(trifluoromethyl)phenoxy)propyl)thio)-2-methylphenoxy)acetate, monosodium salt

Synonym: Seladelpar

MF: C₂₁H₂₂F₃O₅S • Na

FW: 466.4


Purity: ≥95%

UV/Vis.: λ_{max}: 229, 258 nm

Supplied as: A crystalline solid

Storage: -20°C

Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

MBX-8025 (sodium salt) is supplied as a crystalline solid. A stock solution may be made by dissolving the MBX-8025 (sodium salt) in the solvent of choice, which should be purged with an inert gas. MBX-8025 (sodium salt) is slightly soluble in DMSO and acetonitrile.

Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of MBX-8025 (sodium salt) can be prepared by directly dissolving the crystalline solid in aqueous buffers. MBX-8025 (sodium salt) is slightly soluble in PBS (pH 7.2). We do not recommend storing the aqueous solution for more than one day.

Description

MBX-8025 is an agonist of peroxisome proliferator-activated receptor δ (PPAR δ).¹ It is greater than 750- and 2,500-fold selective for PPAR δ over PPAR α and PPAR γ . MBX-8025 (10 mg/kg per day for eight weeks) reduces increases in fasting blood glucose and serum insulin levels, and decreases insulin resistance in Alms1 mutant (*foz/foz*) mice fed an atherogenic diet as a model of diet-induced obesity, type 2 diabetes, and non-alcoholic steatohepatitis (NASH).² It also decreases serum alanine transaminase (ALT), as well as serum and hepatic cholesterol and triglyceride, levels and reduces markers of NASH in the same model.

References

1. Bays, H.E., Schwartz, S., Littlejohn, T., 3rd, *et al.* MBX-8025, a novel peroxisome proliferator receptor- δ agonist: Lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin. *J. Clin. Endocrinol. Metab.* **96(9)**, 2889-2897 (2011).
2. Haczeyni, F., Wang, H., Barn, V., *et al.* The selective peroxisome proliferator-activated receptor-delta agonist seladelpar reverses nonalcoholic steatohepatitis pathology by abrogating lipotoxicity in diabetic obese mice. *Hepatology. Commun.* **1(7)**, 663-674 (2017).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/19/2025

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM